Kornimate/medical-research-clean huggingface dataset:
a study of atezolizumab as neoadjuvant and adjuvant therapy in resectable non-small cell lung cancer (nsclc) - lung cancer mutation consortium (lcmc3)

Conditions: Non-Small Cell Lung Cancer

Summary: this study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable non-small cell lung cancer (nsclc). neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. all participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and chest ct scans, for up to 2 years. all participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.


Eligibility criteria:
inclusion criteria: * pathologically documented stage ib, ii, iiia, or selected iiib, including t3n2 or t4 (by size criteria, not by mediastinal invasion) nsclc * adequate pulmonary and cardiac function * available biopsy of primary tumor with adequate samples * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * nsclc that is clinically t4 by virtue of mediastinal organ invasion or stage iiib by virtue of n3 disease * any prior therapy for lung cancer within 3 years. * prior treatment with anti-pd-1 or pd-l1 therapies * history or risk of autoimmune disease
qualitative analysis of hospital executives, physician administrators, and hospital legal counsels' perceptions of end-of-life care

Conditions: End of Life Care

Summary: interviewing hospital executives, physician administrators and hospital legal counsel who work in a hospital setting (academic, governmental, private or community hospital) about their perceptions concerning current and future end-of-life care provided in their facilities


Eligibility criteria:
inclusion criteria: informant is a hospital executive, physician administrator or hospital legal counsel in a hospital setting (academic, governmental, private or community hospital) and is able to communicate perceptions verbally through use of english language. all participants will likely be nonveterans exclusion criteria:

Keywords: executive administrator perceptions legal counsel end of life
early phase ii study of weekly paclitaxel (bms-181339) in patient with advanced or recurrent head and neck cancer

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer


Eligibility criteria:
inclusion criteria: * patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy and not suitable for further radical local treatment or patients with distant metastases who may have received no or one chemotherapy regimen exclusion criteria: * patients with serious, uncontrolled medical illness
bgem use as blood glucose prediction model in t2dm population of indonesia

Conditions: Diabete Type 2

Summary: using signals from consumer-grade ppg sensors on wrist wearables, smart rings or hearables, bgem® ai model computes the relevant digital biomarkers correlated with the change of blood glucose level to predict a blood glucose result for monitoring and evaluating diabetic risks ukrida in collaboration with actxa \& lif aims to enhance the current model's prediction accuracy to predict the blood glucose levels of individuals almost as accurately as a glucometer. to achieve this, actxa aims to collect data from around 500 individuals with diabetes in this exercise and 400 healthy or undiagnosed (prediabetes/diabetes) individuals.

background powered by our ai-driven algorithm, the actxa's blood glucose evaluation and monitoring (bgem®) is a cloud-based technology that enables wearables with photoplethysmography (ppg) sensors to monitor and evaluate diabetic risk of individuals regularly in a non-invasive way. using signals from consumer-grade ppg sensors on wrist wearables, smart rings or hearables, bgem® ai model computes the relevant digital biomarkers correlated with the change of blood glucose level to predict a blood glucose result for monitoring and evaluating diabetic risks. our previous study has shown the potential of using ppg sensors to detect elevated blood glucose levels among a non-diabetic population1. objective ukrida in collaboration with actxa \& lif to enhance the current model's prediction accuracy to predict the blood glucose levels of individuals almost as accurately as a glucometer. to achieve this, actxa aims to collect data from around 500 individuals with diabetes in this exercise and 400 healthy or undiagnosed (prediabetes/diabetes) individuals, as part of actxa's collaboration with ukrida hospital. with the data collected, our algorithm holds the potential to significantly improve the management of blood glucose levels for people with and without diabetes, ultimately enhancing their overall quality of life.

Eligibility criteria:
inclusion criteria: * age between 18-59 yo * diabetic or non diabetic * healthy enough to undergoes normal daily activity exclusion criteria: * o wears a pacemaker * is currently pregnant * has an infection * has a fever
mandatory hiatoplasty in sleeve gastrectomy for gastro-esophageal reflux disease

Conditions: Postgastrectomy Syndromes; Gastroesophageal Reflux

Summary: the goal of this observational study is to learn about incidence of postoperative gastroesophageal reflux disease in mandatory hiatoplasty performed during gastric sleeve surgery. the main question\[s\] it aims to answer are: * incidence of postoperative gerd in patients undergoing gastric sleeve with mandatory hiatoplasty * comparison of postoperative complication rates, including gerd participants will answer a follow-up questionnaire, about postoperative quality of life


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * gender indistinct. * overweight, obesity grade i, ii, iii, super obesity or super-super obesity. * underwent gastric sleeve with hiatoplasty for obesity management at a high volume tijuana hospital dedicated to bariatric surgery. exclusion criteria: * patient records with incomplete information.

Keywords: incidence complications bariatric surgery obesity
cholecalciferol versus doxercalciferol in the treatment of secondary hyperparathyroidism in chronic kidney disease

Conditions: Renal Osteodystrophy

Summary: the majority of patients with moderate to severe chronic kidney disease (ckd) (stages 3 and 4) develop secondary hyperparathyroidism (2°hpt), but the optimal therapy to control hyperparathyroidism in this group is unknown. the national kidney foundation presented guidelines in 2003 recommending vitamin d supplementation for vitamin d insufficient patients and active vitamin d therapy in patients with sufficient levels. these guidelines are based on opinion since there are no significant trials to determine if vitamin d supplementation is effective in this population. the active vitamin d metabolites doxercalciferol, paricalcitol, and calcitriol have been shown to effectively suppress parathyroid hormone (pth), but have not been compared with vitamin d supplementation with a calciferol (ergocalciferol or cholecalciferol). beyond hyperparathyroidism, small studies suggest vitamin d replacement in vitamin d insufficient non-ckd subjects result in improved pain, feeling of well being, blood pressure and strength. in this proposed study we wish to directly compare the effectiveness of cholecalciferol versus doxercalciferol in suppressing elevated pth levels in subjects with ckd not on dialysis who have vitamin d insufficiency in a three month study. secondary endpoints will be change in blood pressure.

patients with ckd stage 3 were randomly allocated (by blinded group allocation) to either cholecalciferol (4000 u per day for one month then 2000 iu daily thereafter) or doxercalciferol (2.5 mcg po daily. assessments for blood endpoints (primary end point pth; secondary calcium, phosphorus) were done monthly. other assessments (blood pressure) were done at baseline and at 3 months.

Eligibility criteria:
inclusion criteria: * age 18 years old or older, male or female * able to sign informed consent * ckd stage 3 (gfr 30-59 ml/min) or stage 4 (15-29 ml/min) * intact parathyroid hormone level (ipth) \> 100 pg/ml for stage 3 or ipth \> 150 pg/ml for stage 4 * calcidiol levels ≤ 20 ng/ml * ability to ambulate without assistance exclusion criteria: * intact pth \> 400 pg/ml * initial corrected calcium \> 9.7 mg/dl * initial serum phosphorous \> 5.0 mg/dl * initial standardized blood pressure of \> 160/100 * history of significant liver disease or cirrhosis * anticipated requirement for dialysis in 6 months * malabsorption, severe chronic diarrhea, or ileostomy * no calcimimetic or active vitamin d therapy 30 days prior to enrollment * use of digoxin, magnesium containing products, mineral oil, or cholestyramine

Keywords: kidney, parathyroid hormone, vitamin d
autologous adipose-derived adult stromal vascular cell administration for male patients with infertility

Conditions: Azoospermia; Oligozoospermia

Summary: severe oligospermia (oligozoospermia) refer to semen with a low concentration of sperm and is a common finding in male infertility. often semen with a decreased sperm concentration may also show significant abnormalities in sperm morphology and motility that affect male fertility. the purpose of this study is to assess the ability of autologous adipose-derived adult stromal vascular fraction (svf) cells to stimulate sertoli and spermatogonia cells and affect male fertility.

this is an open-label study to evaluate efficiency of administration of autologous adipose-derived adult stromal vascular fraction (svf) in the testis in patients with oligospermia and azoospermia. forty men with several form oligozoospermia and azoospermia will be recruited for the study. 20 patients with same diagnosis served as a control with standard medications.other patients -10 with oligospermia and 10 with azoospermia will receive standard medication and svf injections. the diagnosis of azoospermia (oligospermia) will be established on the basis of two and more semen analysis evaluations done at separate occasions and detailed history taking, physical examination and investigations (blood tests include hormon levels as testosteron. follicle stimulating hormone (fsh), luteinizing hormone (lh). karyotyping and testosterone levels, and may include testicular biopsy or transrectal ultrasound if indicated. this study affect only pretesticular and testicular forms, without chromosomal aberration. svf can produce a lot of cytokines ( as egf, fgf, ngf, pdgf, vegf, igf, gmcsf, gcsf, tgf, erythropoetin, tpo, bmp, hgf, gdf, neurotrophins, msf, sgf, gdf and growth factors) moreover the microvesicles and exosomes released by this cells can prevent cells from apoptosis and stimulate regenerative process of surrounding tissues and cells. svf will be transplanted by an andrological surgeon through a standard surgical approach. subjects will be monitored frequently for a total of one year after cell injection.

Eligibility criteria:
inclusion criteria: * idiopathic oligozoospermia (spermatozoid number \<2x10\^6/ml) - 10 patients * cryptozoospermia/azoospermia - 10 patients exclusion criteria: * age before 18 or after 60 years old * heart insufficiency. stroke (during 1 year) * anemia * blood disease * pelvis bone trauma * chronic diseases in decompensation stage * skin diseases * tuberculosis * hyperprolactinaemia * hyper or hypothyreosis * obstructive zoospermia * sperm stimulating hormone therapy * men with previous surgery in testis * men with infectious genital diseases and anatomical abnormalities of the genital tract * those with major medical problems such as malignancy, hepatitis b . c, etc. hiv * chromosomal aberration (e.g. y microdeletion, trisomy....)

Keywords: autologous stem cell male infertility adipose-derived stem cell azoospermia oligospermia
rhythmic handwriting deficits and general rhythmic abilities in children

Conditions: Developmental Coordination Disorder

Summary: patients with developmental coordination disorder (dcd), a neurodevelopmental disorder that affects motor skills and motor learning (apa, 2013), have been reported to manifest rhythmic deficits in handwriting domain, as well as general rhythmic deficits (i.e., regardless handwriting context per se) (rosenblum \& regev, 2013). accordingly, children with dcd struggle in tasks like synchronising to an external musical rhythm (in rhythm production tasks) or even in discrimination tasks such as detecting beat deviations, i.e., in rhythm perception tasks (inserm collective expertise, 2019). these rhythmic deficits which manifest in a variety of tasks and conditions support the hypothesis of a "generalised dysrhythmia" in dcd, according to which the rhythmic deficits - in perceptual tasks and motor production - could have a common source, namely a mechanism devoted to rhythm processing (a cerebral mechanism involved in the perception of rhythm) and independent of the effectors involved and the type of task considered. however, the nature of the relationships between general rhythmic skills (perceptual and motor) and rhythmic abilities when engaged in handwriting movement is largely unknown in dcd. whether a common source drives these diverse rhythmic deficits remains to explore. if this hypothesis were to be confirmed, this would pave the way for innovative therapeutic tools (e.g., serious games) for training a central rhythmic processing mechanism (rhythm perception), which could positively impact in turn rhythmicity of thandwriting movement in this population.


Eligibility criteria:
inclusion criteria: * children aged 7 to 10 inclusive * children who can read and write * diagnosis of dcd according to dsm-5 criteria (apa, 2015) * native french speaker * living with at least one parent exclusion criteria: * intellectual development disorder confirmed or suspected during the initial evaluation phase in the mpea department. * presence or suspected presence of a visual impairment at the root of the motor skills deficit. * presence or suspected presence of a neurological motor disorder (e.g. sensory impairment, cerebral palsy, muscular dystrophy, degenerative disease). * not affiliated to a social security scheme or not benefiting from such a scheme. * absence of written, informed consent from parents.

Keywords: : developmental coordination disorder rhythm rhythmic skills handwriting
transcranial magnetic stimulation treatment of hoarding disorder

Conditions: Hoarding

Summary: this is multiple baseline study including up to three participants with a primary diagnosis of hoarding disorder. all patients will receive unblinded repetitive transcranial magnetic stimulation study intervention.

study assessments will be conducted at pre-baseline, weekly during baseline assessment (until a stable baseline is established, but not less than 2, 4, and 6 weeks for patients respectively), weekly during treatment, and at post-treatment. magnetic resonance imaging (mri) will be competed at pre-baseline, pre-treatment, and post-treatment. treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation using the neurostar therapy system for 6 weeks employing right-sided, low frequency stimulation (1 hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (dlpfc). neuronavigation will direct coil placement over the dlpfc based upon structural mri.

Eligibility criteria:
inclusion criteria: * diagnosed with hoarding disorder as primary disorder * clinical global impression score \> 3 * saving inventory-revised score \> 39 exclusion criteria: * any contraindication for participation in magnetic resonance imaging or transcranial magnetic stimulation * severe and/or unstable medical or psychiatric condition that require immediate medical attention * diagnosed with current major depressive episode * currently taking psychiatric medication
life-long tele-monitoring of patients with type 2 diabetes mellitus in central greece

Conditions: Diabetes Mellitus, Type 2

Summary: to evaluate whether patients with type 2 diabetes mellitus can be followed by simplified, centralized and large scale tele-monitoring of blood glucose levels and blood pressure, and whether this intervention produces health and economic benefits when introduced without major changes to the existing organization of a large tertiary care center.

the present study aims to examine the clinical and financial effects and the patients' perception and satisfaction of home telemedicine support system for diabetes management versus standard (usual) care. in the intervention group the patients will be provided with a blood glucose meter and a mobile phone and their data will be transferred via the mobile to the regional database and will be assessed by the allocated care team. appropriate counseling on treatment and symptoms or problems related to diabetes will also be provided. measurements of hba1c will be taken to assess glycaemic control while the dietary and the exercise habits will be assessed by the use of questionnaires. in addition the patients' satisfaction from the use of the telemedicine service will be studied. a cost-effective analysis and cost utility analysis will be applied to evaluate the tele-health service compared with the usual care from the health and social perspective. the effect of the tele-health service in the organization structure of the outpatient hospital department will be evaluated with a qualitative study.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes * hba1c \> 53 mmol/mol (7.0 % according to ngsp) * capability to use the devices provided * being cognitively able to participate * capability of filling in questionnaires in german or greek language * absence of severe comorbidity prevalent on diabetes with life expectancy \< 12 months exclusion criteria: * pregnancy

Keywords: diabetes mellitus, type 2 telemedicine
comparative efficacy and safety of extensive electro-anatomical guided pulsed field ablation versus radiofrequency ablation in persistent atrial fibrillation

Conditions: Atrial Fibrillation (AF)

Summary: this multicenter, randomized controlled trial aims to compare the efficacy and safety of extensive electro-anatomical guided pulsed field ablation (ext-pfa) with traditional radiofrequency ablation (rf) in treating persistent atrial fibrillation (peaf). the trial seeks to determine if ext-pfa, which integrates anatomical and electrogram-guided strategies, can provide superior outcomes in terms of safety and effectiveness compared to the standard rf ablation approach.


Eligibility criteria:
inclusion criteria: 1.adults aged 18-80 years diagnosed with persistent atrial fibrillation. 2.ineffectiveness or intolerance to at least one class i or iii anti-arrhythmic drug. exclusion criteria: 1. major valvular diseases needing surgical intervention. 2. presence of a left atrial thrombus on recent imaging. 3. recent myocardial infarction or severe heart failure (lvef ≤ 30%). 4. current severe infection.

Keywords: atrial fibrillation pulsed field ablation radiofrequency ablation
molecular mechanism study of uterine sarcoma

Conditions: Uterine Sarcoma

Summary: the purpose of this project was to use multi-omics technology to screen the key factors for the occurrence and development of uterine sarcoma.

uterine sarcomas are rare mesenchymal neoplasms in the female genital system, accounting for about 1% of female reproductive tract malignancies and 3%\~7% of uterine malignancies. subtypes of uterine sarcoma are leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. uterine leiomyosarcoma is the most common uterine sarcoma, accounting for about 1% to 2% of all uterine malignancies. uterine sarcomas differ in histologic appearance and clinical behavior. the incidence of uterine sarcoma is low and the prognosis is poor. its manifestations mainly include abnormal vaginal bleeding, abdominal pain and abdominal mass, but none of these symptoms are specific. for uterine sarcoma, there are no diagnostic serum markers and imaging features and the diagnosis of uterine sarcoma still mainly depends on postoperative pathological results. however, with the development of omics technology, immunophenotypes and molecular characterization of uterine sarcomas have increasingly been utilized to improve diagnostic classification and prognostication in uterine sarcomas. uterine leiomyosarcoma, the most common subtype of uterine sarcoma, does not have a single defining molecular abnormality. this project intends to use multi-omics technology to screen the key factors for the occurrence, development, and malignant transformation of uterine sarcoma, especially uterine leiomyosarcoma, and to map the interaction network of cell signaling pathways. it provides key molecular markers for the early assessment of recurrence and malignant transformation of uterine myoma after conservative treatment, and provides a molecular mechanism basis for finding solutions to prevent the progression and malignant transformation.

Eligibility criteria:
inclusion criteria: 1. age 18 or older; 2. newly treated or recurenced uterine sarcoma. exclusion criteria: 1. diagnosis of other malignancies within the past 5 years; 2. history of pelvic or vaginal radiation therapy; 3. known high-grade lesions of the cervix and endometrium.
tobacco approach avoidance training for adolescent smokers-1

Conditions: Tobacco Use Disorder

Summary: this is a two part study. study 1 will compare approach avoidance training (aat) responses in smokers and nonsmokers in order to confirm that adolescent smokers experience cognitive bias towards tobacco-related stimuli.


Eligibility criteria:
inclusion criteria: * between ages 13-18 years * able to read and write in english. * smokers: smoking 5 or more cigarettes daily for at least 6 months; baseline urine cotinine levels \> 500 ng/ml * nonsmokers: never smokers; baseline urine cotinine levels \< 50 ng/ml exclusion criteria: * current criteria for dependence on another psychoactive substance * current diagnosis of psychosis, major depression or panic disorder * regular use of any psychoactive drugs including anxiolytics and antidepressants unless the medication has been taken consistently for 2 months, is currently being monitored by a physician, and the condition for which the medication is taken is considered to be stable * pregnant or lactating girls, based on self report.

Keywords: nicotine smoking adolescent tobacco